Table 3.
AMD Results for Matched Clinical Samples by Culture Results
| Clinical Sample Testeda (Matched Patient and Culture Status) |
No. Tested | No. AMD +ve (%) |
|---|---|---|
| Serum (blood culture –ve) | 52 | 7 (13) |
| Serum (blood culture +ve) | 62 | 24 (39) |
| Serum (septic shockb +ve) | 19 | 13 (68) |
| Serum (fatal melioidosis) | 4 | 3 (75) |
| Urine (blood culture –ve) | 31 | 16 (52) |
| Urine (blood culture +ve) | 25 | 18 (72) |
| Urine (septic shockb +ve) | 10 | 9 (90) |
| Urine (urine culture –ve) | 74 | 44 (59) |
| Urine (urine culture +ve) | 19 | 15 (79) |
| Sputum (sputum culture –ve) | 5 | 2 (40) |
| Sputum (sputum culture +ve) | 27 | 23 (85) |
| Skin swabs (swabs culture +ve) | 24 | 12 (50) |
| Joint fluid (fluid culture +ve) | 8 | 5 (63) |
| Other pus/tissue (culture +ve) | 24 | 20 (83) |
Abbreviation: AMD, Active Melioidosis Detect.
Only including those where AMD sample was taken within 72 hours of the matched culture sample. Only 1 sample per individual for each clinical specimen (where done), so duplicate samples such as serial serum, urine, or sputum were removed.
Melioidosis septic shock, as defined in Currie et al. [17]. Serum and urine samples were taken within 72 hours of admission with septic shock.